10-Q

ROC

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


	For the transition period from		to

Commission File Number: 000-50484

MEI Pharma, Inc.

(Exact name of registrant as specified in its charter)



DELAWARE		51-0407811
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

11455 El Camino Real, San Diego, CA 92130

(Address of principal executive offices) (Zip Code)

(858) 369-7100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.00000002 par value

MEIP

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

As of November 8, 2021, the number of shares outstanding of the issuer’s common stock, $0.00000002 par value, was 112,721,212.

Table of Contents

MEI PHARMA, INC.

Table of Contents



		Page

PART I	FINANCIAL INFORMATION		3

Item 1:	Financial Statements (Unaudited)		3

	Condensed Balance Sheets as of September 30, 2021 and June 30, 2021		3

	Condensed Statements of Operations for the three months ended September 30, 2021 and 2020		4

	Condensed Statements of Stockholders’ Equity for the three months ended September 30, 2021 and 2020		5

	Condensed Statements of Cash Flows for the three months ended September 30, 2021 and 2020		6

	Notes to Condensed Financial Statements		7

Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations		19

Item 3:	Quantitative and Qualitative Disclosures about Market Risk		32

Item 4:	Controls and Procedures		32

PART II	OTHER INFORMATION		33

Item 1:	Legal Proceedings		33

Item 1A:	Risk Factors		33

Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds		33

Item 3:	Defaults upon Senior Securities		33

Item 4:	Mine Safety Disclosures		33

Item 5:	Other Information

SEC Form 10-Q filed by MEI Pharma, Inc.